Piramal Pharma Limited Announces Impressive Q2 and H1 FY25 Results
Piramal Pharma Limited (NSE: PPLPHARMA, BSE: 543635), a prominent player in the global pharmaceuticals and wellness industry, has reported its financial results for the Second Quarter (Q2) and Half Year (H1) of FY25, indicating a notable upward trend in its performance.
Financial Highlights from Q2 FY25
During the second quarter, the company's revenue from operations reached ?2,242 Crore, showing a remarkable 17% growth compared to ?1,911 Crore in Q2 FY24. This growth is primarily attributed to a robust performance in the Contract Development and Manufacturing Organization (CDMO) sector.
Impressive Grow in EBITDA
The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) also saw significant improvement, rising by 28% from the previous year to reach ?403 Crore. The EBITDA margin stood at 18%, reflecting a year-on-year increase of around 150 basis points. This positive trend is largely due to strategic cost optimization initiatives and enhanced operational efficiency.
Highlights from the Sustainability Report
Piramal Pharma has released its FY24 Sustainability Report that aligns with Global Reporting Initiative (GRI) standards and supports the Science Based Targets initiative (SBTi). This report underscores the company’s commitment to reducing Greenhouse Gas (GHG) emissions, aligning with the 1.5º decarbonization pathway.
CEO Remarks
Nandini Piramal, the Chairperson of Piramal Pharma Limited, emphasized the ongoing growth momentum of the company's CDMO business. She stated that the business has experienced strong demand for innovative products and on-patent commercial revenues. To capitalize on this demand, the company is investing US$80 million to expand its Lexington facility, which is anticipated to be completed by the end of FY27.
Strategic Business Developments
In addition to the revenue growth, the company is witnessing consistent volume growth in its Inhalation Anesthesia products aimed at the U.S. and emerging markets. Furthermore, in the India Consumer Healthcare (ICH) segment, the organization continues to see a growing demand for power brands, resulting in an 18% year-over-year increase in this category.
Investment in Future Growth
As Piramal Pharma looks towards the future, the company has set ambitious targets to achieve US$2 billion in revenue with a 25% EBITDA margin by FY30. This strategy will include expanding its offerings across various healthcare solutions and enhancing its distribution network.
Quarterly Earnings Call Details
To discuss these results in more detail, Piramal Pharma will host a conference call with investors and analysts. The call is scheduled for October 24, 2024, from 5:00 PM to 5:45 PM IST. Participants interested in joining the call can dial the appropriate numbers based on their location.
About Piramal Pharma Limited
Piramal Pharma Limited offers a wide array of differentiated products and services globally, supported by 17 production facilities and a distribution network reaching over 100 countries. It includes divisions such as Piramal Pharma Solutions and Piramal Critical Care, focusing on providing innovative solutions in the pharmaceutical space.
Frequently Asked Questions
What are the key financial highlights from Q2 FY25?
Piramal Pharma reported ?2,242 Crore in revenue from operations, reflecting a 17% growth year-on-year.
How did EBITDA perform in Q2 FY25?
EBITDA saw a growth of 28%, reaching ?403 Crore with an EBITDA margin of 18%.
What are the sustainability commitments of Piramal Pharma?
The company is committed to reducing GHG emissions, highlighted in their FY24 Sustainability Report.
What investments are planned for future growth?
Piramal Pharma is planning an US$80 million expansion of its Lexington facility to enhance its sterile fill-finish capabilities.
How does Piramal Pharma define its strategic goals for FY30?
The company aims to achieve US$2 billion in revenue with a 25% EBITDA margin by FY30.
